# Breast Tumor Cellularity Assessment using Deep Neural Networks

**Authors:** Alexander Rakhlin, Aleksei Tiulpin, Alexey A. Shvets, Alexandr A., Kalinin, Vladimir I. Iglovikov, Sergey Nikolenko

arXiv: 1905.01743 · 2019-09-04

## TL;DR

This paper presents three novel deep learning approaches for automatic breast tumor cellularity assessment, demonstrating significant improvements over previous methods and potential to assist pathologists in clinical diagnosis.

## Contribution

Introduces and validates three deep learning methods for automated tumor cellularity scoring, outperforming existing approaches on a large dataset.

## Key findings

- Best method achieved Cohen's kappa of 0.70
- Intra-class correlation coefficient of 0.89
- Outperformed previous literature in accuracy

## Abstract

Breast cancer is one of the main causes of death worldwide. Histopathological cellularity assessment of residual tumors in post-surgical tissues is used to analyze a tumor's response to a therapy. Correct cellularity assessment increases the chances of getting an appropriate treatment and facilitates the patient's survival. In current clinical practice, tumor cellularity is manually estimated by pathologists; this process is tedious and prone to errors or low agreement rates between assessors. In this work, we evaluated three strong novel Deep Learning-based approaches for automatic assessment of tumor cellularity from post-treated breast surgical specimens stained with hematoxylin and eosin. We validated the proposed methods on the BreastPathQ SPIE challenge dataset that consisted of 2395 image patches selected from whole slide images acquired from 64 patients. Compared to expert pathologist scoring, our best performing method yielded the Cohen's kappa coefficient of 0.70 (vs. 0.42 previously known in literature) and the intra-class correlation coefficient of 0.89 (vs. 0.83). Our results suggest that Deep Learning-based methods have a significant potential to alleviate the burden on pathologists, enhance the diagnostic workflow, and, thereby, facilitate better clinical outcomes in breast cancer treatment.

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/1905.01743/full.md

## Figures

32 figures with captions in the complete paper: https://tomesphere.com/paper/1905.01743/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/1905.01743/full.md

---
Source: https://tomesphere.com/paper/1905.01743